Source-grounded facts extracted from GridAI Technologies Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
GridAI Technologies Corp. entered into Debt Settlement and Subscription Agreement with 1396974 BC Ltd. (effective 2026-05-14).
“On May 14, 2026, the Company and the Lender entered into a Debt Settlement and Subscription Agreement (the “Settlement Agreement”)”
GridAI Technologies Corp. entered into Additional Purchase Agreement with purchasers identified therein valued at approximately $5,250,000 (effective 2026-05-11).
“On May 11, 2026, the Company entered into a securities purchase agreement (the “Additional Purchase Agreement”) with the purchasers identified therein (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”) pursuant to which the Company will sell to the Purchasers in private placements an aggregate of (i) 87,260 shares of common stock, (ii) pre-funded warrants to purchase up to an aggregate of 1,745,199 shares of common stock (the “Pre-Funded Warrants”) and (iii) common stock purchase warrants to purchase up to an aggregate of 1,832,459 shares of common stock (the “Common Warrants”) for gross proceeds to the Company of approximately $5,250,000.”
GridAI Technologies Corp. entered into Purchase Agreements with purchasers identified therein valued at approximately $2,540,000 (effective 2026-05-08).
“On May 8, 2026, May 11, 2026 and May 12, 2026, GridAI Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with purchasers identified therein (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”) pursuant to which the Company agreed to sell to the Purchasers in private placements an aggregate of (i) 74,000 shares of common stock, (ii) pre-funded warrants to purchase up to an aggregate of 1,196,001 shares of common stock (the “Pre-Funded Warrants”) and (iii) common stock purchase warrants to purchase up to an aggregate of 1,270,001 shares of common stock (the “Common Warrants”) for gross proceeds to the Company of approximately $2,540,000.”
GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 22, 2026, GridAI Technologies Corp. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compl”
GridAI Technologies Corp. faced acceleration on revolving credit of $1,014,675 with 1396974 BC Ltd. maturing January 31, 2026.
“On April 1, 2026, the Company received a demand letter from the Lender’s counsel, asserting that the Company is in default of the Revolving Loan Agreement as the Maturity Date has passed and the amounts due under the Revolving Loan Agreement have not been repaid, and demanding the Company to pay a total sum of $1,014,675, which includes the principal amounts received by the Company ($700,000), interest and a 20% increase of these amounts due to the default pursuant to the terms of Revolving Loan Agreement.”
GridAI Technologies Corp. completed a disposition involving ImmunogenX, LLC and each of the individuals or entities who are the former shareholders of ImmunogenX, Inc. (closed 2025-12-31).
“On December 31, 2025, the Company, Immuno LLC and the Shareholders completed the transactions contemplated by the Rescission Agreement, as amended by the Rescission Agreement Amendment (the “Transaction”), including the transfer by the Coamny to the Shareholders of all of the issued and outstanding membership interests of Immuno LLC held by the Company.”
GridAI Technologies Corp.: Company amended its Certificate of Incorporation to change name from Entero Therapeutics, Inc. to GridAI Technologies Corp (effective 2025-12-01).
“The Company amended its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a change of the Company’s name from “Entero Therapeutics, Inc.” to “GridAI Technologies Corp.” (the “Name Change”).”
GridAI Technologies Corp. incurred debt of $500,000 with an investor at does not bear interest maturing one year and one day after its date of issuance.
“Initial Closing took place on October 17, 2025, pursuant to which the Company sold to the Investor: (i) a Note in the principal amount of $500,000”
GridAI Technologies Corp.: Filed Certificate of Designation creating Series H Preferred Stock (effective 2025-10-01).
“On October 1, 2025, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware.”
GridAI Technologies Corp.: Amended certificate of incorporation to effect a 1-for-3 reverse stock split (effective 2025-08-18).
“On August 14, 2025, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”
GridAI Technologies Corp. amended revolving credit of $2,436,338.30 with Mattress Liquidators Inc. maturing April 9, 2028.
“enter into amended and restated loan documents (collectively, the “Amended and Restated Loan Documents”) dated April 9, 2025 which provide for, among others, a revolving loan of $2,436,338.30 (the “Commitment”) to ImmunogenX, LLC, to be repaid and the principal amount thereof reborrowed before the earliest of: (i) April 9, 2028; (ii) the date ImmunogenX, LLC prepays”
GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 11, 2025, Entero Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of ($3,876,738) as reported in the Company’s Annual Report on Form 10-K for the period ended December 31, 2024 was below the required minimum of $2.5 million, and because, as of April 10, 2025 the C”
GridAI Technologies Corp. received a nasdaq noncompliance notice notice regarding shareholders (rules 5620(a)).
“January 7, 2025, a formal letter from Nasdaq notifying the Company that it did not comply with Nsadaq Listing Rule 5620(a) (the “Annual Meeting Rule”), which requires that it hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. On February 21, 2025, the Company submitted to the Staff a plan of compliance which described the circumstances under which it became noncompliant with the Annual Meeting Rule and the Company’s plan with which it will regain compliance. The Staff in its letter dated March 3, 2025 determined to grant the Company an exte”
GridAI Technologies Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).
“s days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until March 5, 2025, to regain compliance with the Minimum Bid Price Requirement. On March 6, 2025, the Company received a letter from Nasdaq (the “Extension Notice”) advising that the Company has been granted a 180-day extension, or until Septemb”
Anna Skowron was appointed as Chief Financial Officer at GridAI Technologies Corp..
“on March 3, 2025, the Company appointed Ms. Anna Skowron as Chief Financial Officer of the Company, effective as of March 7, 2025”
Sarah Romano resigned as Chief Financial Officer at GridAI Technologies Corp..
“On March 3, 2025, Ms. Sarah Romano informed the Company of her resignation as Chief Financial Officer of the Company, effective as of March 7, 2025.”
Richard Joel Paolone was appointed as Interim Chief Executive Officer and Chairman of the Board at GridAI Technologies Corp..
“On February 12, 2025, Richard Joel Paolone was appointed to serve as Interim Chief Executive Officer of the Company and Chairman of the Board, effective immediately.”
James Sapirstein was terminated as Chief Executive Officer at GridAI Technologies Corp..
“On February 12, 2025, the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”) terminated James Sapirstein as Chief Executive Officer of the Company, without cause, effective immediately.”
GridAI Technologies Corp. incurred revolving credit of $2,000,000 with 1396974 BC Ltd. at 18% per annum maturing January 31, 2026.
“the Company. Pursuant to and under the terms of the Revolving Loan Agreement, the Company issued to the Lender a revolving note dated January 27, 2025 in the principal amount of $2,000,000 (the “Revolving Note” and such amount, the “Total Outstanding Amount”). This transaction is referred to as the “Financing.” The Company shall use the proceeds from the Financing”
GridAI Technologies Corp. underwent a change of control involving 1396974 BC Ltd..
“Upon the closing of the Financing, the Lender acquired control of the Company by appointing a majority of the Company’s Board of Directors.”
Richard Joel Paolone was appointed as director at GridAI Technologies Corp..
“the Company’s Board of Directors appointed Manpreet Uppal, Alson Niu and Richard Joel Paolone as directors of the Company”
Alson Niu was appointed as director at GridAI Technologies Corp..
“the Company’s Board of Directors appointed Manpreet Uppal, Alson Niu and Richard Joel Paolone as directors of the Company”
Manpreet Uppal was appointed as director at GridAI Technologies Corp..
“the Company’s Board of Directors appointed Manpreet Uppal, Alson Niu and Richard Joel Paolone as directors of the Company”
James Sapirstein resigned as director at GridAI Technologies Corp..
“On February 3, 2025 (i) each of Timothy Ramdeen, Alastair Riddell and James Sapirstein resigned as directors of the Company”
Alastair Riddell resigned as director at GridAI Technologies Corp..
“On February 3, 2025 (i) each of Timothy Ramdeen, Alastair Riddell and James Sapirstein resigned as directors of the Company”
Timothy Ramdeen resigned as director at GridAI Technologies Corp..
“On February 3, 2025 (i) each of Timothy Ramdeen, Alastair Riddell and James Sapirstein resigned as directors of the Company”
GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).
“le or Standard; Transfer of Listing. On January 7, 2025, Entero Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Company’s 2023 fiscal year end. The Company has until February 21, 2025, which is 45 days from the date of the Notice, to submit a plan to regain compliance and, if Nasdaq accepts the plan, it ma”
GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).
“Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5620(a), due to the Company not holding an annual meeting of stockholders in 2024 within one year of the Compa”
Chaitan Khosla resigned as Director at GridAI Technologies Corp..
“On August 16, 2024, Chaitan Khosla resigned as a member of the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”), effective immediately.”
Timothy R. Ramdeen was appointed as Director at GridAI Technologies Corp..
“appointed Timothy R. Ramdeen as a member of the Board.”
Jack Syage was terminated as President at GridAI Technologies Corp..
“and (ii) the offer letter, dated March 13, 2024, by and between the Company and President Jack Syage”
James Sapirstein was terminated as Chief Executive Officer at GridAI Technologies Corp..
“the Board approved the termination of (i) the employment agreement, dated October 8, 2019, by and between the Company and Chief Executive Officer James Sapirstein”
Terry Coelho resigned as Director at GridAI Technologies Corp..
“On August 2, 2024, Charles J. Casamento and Terry Coelho resigned as members of the Board of the Company, effective immediately.”
Charles J. Casamento resigned as Director at GridAI Technologies Corp..
“On August 2, 2024, Charles J. Casamento and Terry Coelho resigned as members of the Board of the Company, effective immediately.”
Jack Syage resigned as Chief Scientific Officer at GridAI Technologies Corp..
“Dr. Jack Syage, the Company’s Chief Scientific Officer, President and member of the Board, whereby he tendered his resignation from the role of Chief Scientific Officer of the Company, effective immediately.”
Jack Syage changed role as Chief Scientific Officer at GridAI Technologies Corp..
“transitioned Dr. Syage from the role of Chief Operating Officer to the newly appointed role of Chief Scientific Officer, effective immediately.”
GridAI Technologies Corp.: Company changed its corporate name from First Wave BioPharma, Inc. to Entero Therapeutics, Inc. via amendment to Amended and Restated Certificate of Incorporation (effective 2024-05-17).
“On May 15, 2024, First Wave BioPharma, Inc. (the “Company”) filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from "First Wave BioPharma, Inc." to "Entero Therapeutics, Inc." (the "Name Change Amendment"). Pursuant ot the Name Change Amendment, this name change is effective as of May 17, 2024.”
GridAI Technologies Corp. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2024-05-10).
“On May 10, 2024, First Wave BioPharma, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)”
GridAI Technologies Corp. entered into Purchase Agreement with certain purchasers valued at approximately $0.9 million (effective 2024-05-10).
“On May 10, 2024, First Wave BioPharma, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers”
GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5635(d)).
“March 19, 2024, the Company received a Letter of Reprimand (the “Letter”) from the Staff in accordance with Nasdaq’s Listing Rule 5810(c)(4). The Staff’s determination relates to the offering and issuance by the Company (the “Offering”) of an aggregate of: (i) 610,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,675,000 shares of Common Stock (the “Pre-Funded Warrant Shares”) and (iii) common warrants (the “Warrants”) to purchase up to an aggregat”
GridAI Technologies Corp.: Filed Certificate of Designation for Series G Non-Voting Convertible Preferred Stock, establishing its preferences, rights, and limitations (effective 2024-03-13).
“Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Certificate of Designation On March 13, 2024, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series G Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Merger referenced in Item 1.01 above.”
GridAI Technologies Corp. completed an acquisition involving ImmunogenX, Inc. (closed 2024-03-13).
“On March 13, 2024, the Company completed its business combination with ImmunogenX.”
GridAI Technologies Corp. entered into Merger Agreement with ImmunogenX.
“Pursuant to the terms of the Merger Agreement, we are required to recommend that our stockholders approve the conversion of shares of our Series G Preferred Stock into shares of our Common Stock.”
James Sapirstein changed role as President at GridAI Technologies Corp..
“James Sapirstein, the Company’s Chief Executive Officer and Chairman, had served as the Company’s President until the appointment of Dr. Syage.”
Chaitan Khosla was appointed as Member of the Board at GridAI Technologies Corp..
“appointed (i) Jack Syage, PhD. as the Company’s President and Chief Operating Officer and as a member of the Board and (ii) Chaitan Khosla as a member of the Board”
Jack Syage was appointed as Member of the Board at GridAI Technologies Corp..
“appointed (i) Jack Syage, PhD. as the Company’s President and Chief Operating Officer and as a member of the Board”
Jack Syage was appointed as President and Chief Operating Officer at GridAI Technologies Corp..
“appointed (i) Jack Syage, PhD. as the Company’s President and Chief Operating Officer and as a member of the Board”
GridAI Technologies Corp. entered into Purchase Agreement with certain purchasers (effective 2024-03-03).
“On March 3, 2024, First Wave BioPharma, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering (the “Offering”), an aggregate of (i) 173,100 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 352,525 shares of Common Stock (the “Pre-Funded Warrant Shares”).”
GridAI Technologies Corp. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2024-03-03).
“On March 3, 2024, First Wave BioPharma, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers pursuant to which the Company agreed to sell, in a registered direct offering (the “Offering”), an aggregate of (i) 173,100 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 352,525 shares of Common Stock (the “Pre-Funded Warrant Shares”).”
GridAI Technologies Corp.: Filed amendment to increase authorized shares and effect a 1-for-20 reverse stock split (effective 2023-12-18).
“On December 13, 2023, the Company filed the Amendment to its Charter with the Secretary of State of the State of Delaware to increase the total number of authorized shares of Common Stock by 50,000,000 shares to 100,000,000 shares and to effect a reverse stock split of its Common Stock at a ratio of 1-to-20 (the “Reverse Stock Split”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.